In vitro analysis on inhibitory effect of sodium arsenite combined with astragaloside IV on HepG2 liver cancer cells

From the in vitro level, this paper explores the synergistic inhibitory effects and mechanisms of sodium arsenite (NaAsO2) and astragaloside IV(AS-IV) on HepG2 cells. By screening the optimal concentration of each drug, the authors tested the combined and separate effects of the two drugs on HepG2 c...

Full description

Saved in:
Bibliographic Details
Published in:Alexandria engineering journal 2021-12, Vol.60 (6), p.5749-5764
Main Authors: Guo, Zhiwei, Xia, Yajuan, Hao, Guang, Gao, Zhenzhen, Li, Ran, Yang, Ying
Format: Article
Language:English
Subjects:
Astragaloside IV (AS-IV)
Combined treatment
Inhibitory effect
Liver cancer
Mechanism
Sodium Arsenite (NaAsO2)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c406t-604b8d537cca83d6a4c4f9b707db1d0b9c7e940abfc15f5d726e6c8d87c02c8d3
cites cdi_FETCH-LOGICAL-c406t-604b8d537cca83d6a4c4f9b707db1d0b9c7e940abfc15f5d726e6c8d87c02c8d3
container_end_page 5764
container_issue 6
container_start_page 5749
container_title Alexandria engineering journal
container_volume 60
creator Guo, Zhiwei
Xia, Yajuan
Hao, Guang
Gao, Zhenzhen
Li, Ran
Yang, Ying
description From the in vitro level, this paper explores the synergistic inhibitory effects and mechanisms of sodium arsenite (NaAsO2) and astragaloside IV(AS-IV) on HepG2 cells. By screening the optimal concentration of each drug, the authors tested the combined and separate effects of the two drugs on HepG2 cell proliferation, migration and invasion, cell cycle and apoptosis, as well as key genes and proteins of the PI3K/AKT/mTOR pathway (PI3K, p-PI3K, AKT, p-AKT, mTOR, and p-mTOR). The CCK-8 test and Transwell tests show that: the separate and joint uses of NaAsO2 and AS-IV reduced the viability and migration of cells to different degrees (p all 
doi_str_mv 10.1016/j.aej.2021.03.043
format article
fullrecord <record><control><sourceid>elsevier_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_6a23d1d194514baaa3f0e0675a69af49</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1110016821002003</els_id><doaj_id>oai_doaj_org_article_6a23d1d194514baaa3f0e0675a69af49</doaj_id><sourcerecordid>S1110016821002003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-604b8d537cca83d6a4c4f9b707db1d0b9c7e940abfc15f5d726e6c8d87c02c8d3</originalsourceid><addsrcrecordid>eNp9kMFO3DAQhnMACQQ8ADe_wKbjxHES9VShFlZC6gW4WhN7DBNlY2S7W-3b18sijvXllzz6P818VXUroZYg9be5RprrBhpZQ1uDas-qSyklbMpwuKhuUpqhvK4f1agvq7xdxZ5zDAJXXA6Jkwir4PWNJ84hHgR5TzaL4EUKjv_sBMZEK2cSNuwmXsmJv5zfBKYc8RWXkNiR2L4cMQ_0ft-IhfcUhcXVHoOWJV1X5x6XRDefeVU9__r5dPewefx9v7378bixCnTeaFDT4Lq2txaH1mlUVvlx6qF3k3QwjbanUQFO3srOd65vNGk7uKG30JRsr6rtiesCzuY98g7jwQRk8_ER4qvBmNkuZDQ2rZNOjqqTakLE1gOB7jvUI3o1FpY8sWwMKUXyXzwJ5mjezKaYN0fzBlpTzJfO91OHypF7pmiSZSoeHMcitWzB_2n_A12CjyI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>In vitro analysis on inhibitory effect of sodium arsenite combined with astragaloside IV on HepG2 liver cancer cells</title><source>Elsevier ScienceDirect Journals</source><creator>Guo, Zhiwei ; Xia, Yajuan ; Hao, Guang ; Gao, Zhenzhen ; Li, Ran ; Yang, Ying</creator><creatorcontrib>Guo, Zhiwei ; Xia, Yajuan ; Hao, Guang ; Gao, Zhenzhen ; Li, Ran ; Yang, Ying</creatorcontrib><description>From the in vitro level, this paper explores the synergistic inhibitory effects and mechanisms of sodium arsenite (NaAsO2) and astragaloside IV(AS-IV) on HepG2 cells. By screening the optimal concentration of each drug, the authors tested the combined and separate effects of the two drugs on HepG2 cell proliferation, migration and invasion, cell cycle and apoptosis, as well as key genes and proteins of the PI3K/AKT/mTOR pathway (PI3K, p-PI3K, AKT, p-AKT, mTOR, and p-mTOR). The CCK-8 test and Transwell tests show that: the separate and joint uses of NaAsO2 and AS-IV reduced the viability and migration of cells to different degrees (p all &lt; 0.05). The scratch test results show that: although the migration rate in each treatment group declined, only NaAsO2 + AS-IV group witnessed a significant decline in migration rate (p &lt; 0.05); the percentage of S phase cells and apoptosis rate both increased significantly in each treatment group (p all &lt; 0.05). GNGT1, PI3K, p-PI3K, AKT, p-AKT, mTOR, and p-mTOR were expressed in each treatment group; Among them, GNGT1 mRNA expression increased in each treatment group, while the expressions of PI3K, p-PI3K, AKT, p-AKT, mTOR and p-mTOR gene proteins decreased in each treatment group; the indices changed most significantly in the NaAsO2 + AS-IV group (p all &lt; 0.05). By the inhibitory effect of each drug on HepG2 cells, the treatment groups could be ranked as NaAsO2 + AS-IV group &gt; NaAsO2 group &gt; AS-IV group; GNGT1 siRNA group had an opposite trend with each treatment group. From in vitro level, the above results confirm that NaAsO2 and AS-IV can inhibit HepG2, and the two drugs has a synergistic effect. In addition, the two drugs could inhibit HepG2 cells through the PI3K/AKT/mTOR signaling pathway; GNGT1 participates in the regulation of that signaling pathway.</description><identifier>ISSN: 1110-0168</identifier><identifier>DOI: 10.1016/j.aej.2021.03.043</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Astragaloside IV (AS-IV) ; Combined treatment ; Inhibitory effect ; Liver cancer ; Mechanism ; Sodium Arsenite (NaAsO2)</subject><ispartof>Alexandria engineering journal, 2021-12, Vol.60 (6), p.5749-5764</ispartof><rights>2021 THE AUTHORS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-604b8d537cca83d6a4c4f9b707db1d0b9c7e940abfc15f5d726e6c8d87c02c8d3</citedby><cites>FETCH-LOGICAL-c406t-604b8d537cca83d6a4c4f9b707db1d0b9c7e940abfc15f5d726e6c8d87c02c8d3</cites><orcidid>0000-0002-5520-1307</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1110016821002003$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27901,27902,45756</link.rule.ids></links><search><creatorcontrib>Guo, Zhiwei</creatorcontrib><creatorcontrib>Xia, Yajuan</creatorcontrib><creatorcontrib>Hao, Guang</creatorcontrib><creatorcontrib>Gao, Zhenzhen</creatorcontrib><creatorcontrib>Li, Ran</creatorcontrib><creatorcontrib>Yang, Ying</creatorcontrib><title>In vitro analysis on inhibitory effect of sodium arsenite combined with astragaloside IV on HepG2 liver cancer cells</title><title>Alexandria engineering journal</title><description>From the in vitro level, this paper explores the synergistic inhibitory effects and mechanisms of sodium arsenite (NaAsO2) and astragaloside IV(AS-IV) on HepG2 cells. By screening the optimal concentration of each drug, the authors tested the combined and separate effects of the two drugs on HepG2 cell proliferation, migration and invasion, cell cycle and apoptosis, as well as key genes and proteins of the PI3K/AKT/mTOR pathway (PI3K, p-PI3K, AKT, p-AKT, mTOR, and p-mTOR). The CCK-8 test and Transwell tests show that: the separate and joint uses of NaAsO2 and AS-IV reduced the viability and migration of cells to different degrees (p all &lt; 0.05). The scratch test results show that: although the migration rate in each treatment group declined, only NaAsO2 + AS-IV group witnessed a significant decline in migration rate (p &lt; 0.05); the percentage of S phase cells and apoptosis rate both increased significantly in each treatment group (p all &lt; 0.05). GNGT1, PI3K, p-PI3K, AKT, p-AKT, mTOR, and p-mTOR were expressed in each treatment group; Among them, GNGT1 mRNA expression increased in each treatment group, while the expressions of PI3K, p-PI3K, AKT, p-AKT, mTOR and p-mTOR gene proteins decreased in each treatment group; the indices changed most significantly in the NaAsO2 + AS-IV group (p all &lt; 0.05). By the inhibitory effect of each drug on HepG2 cells, the treatment groups could be ranked as NaAsO2 + AS-IV group &gt; NaAsO2 group &gt; AS-IV group; GNGT1 siRNA group had an opposite trend with each treatment group. From in vitro level, the above results confirm that NaAsO2 and AS-IV can inhibit HepG2, and the two drugs has a synergistic effect. In addition, the two drugs could inhibit HepG2 cells through the PI3K/AKT/mTOR signaling pathway; GNGT1 participates in the regulation of that signaling pathway.</description><subject>Astragaloside IV (AS-IV)</subject><subject>Combined treatment</subject><subject>Inhibitory effect</subject><subject>Liver cancer</subject><subject>Mechanism</subject><subject>Sodium Arsenite (NaAsO2)</subject><issn>1110-0168</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kMFO3DAQhnMACQQ8ADe_wKbjxHES9VShFlZC6gW4WhN7DBNlY2S7W-3b18sijvXllzz6P818VXUroZYg9be5RprrBhpZQ1uDas-qSyklbMpwuKhuUpqhvK4f1agvq7xdxZ5zDAJXXA6Jkwir4PWNJ84hHgR5TzaL4EUKjv_sBMZEK2cSNuwmXsmJv5zfBKYc8RWXkNiR2L4cMQ_0ft-IhfcUhcXVHoOWJV1X5x6XRDefeVU9__r5dPewefx9v7378bixCnTeaFDT4Lq2txaH1mlUVvlx6qF3k3QwjbanUQFO3srOd65vNGk7uKG30JRsr6rtiesCzuY98g7jwQRk8_ER4qvBmNkuZDQ2rZNOjqqTakLE1gOB7jvUI3o1FpY8sWwMKUXyXzwJ5mjezKaYN0fzBlpTzJfO91OHypF7pmiSZSoeHMcitWzB_2n_A12CjyI</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Guo, Zhiwei</creator><creator>Xia, Yajuan</creator><creator>Hao, Guang</creator><creator>Gao, Zhenzhen</creator><creator>Li, Ran</creator><creator>Yang, Ying</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-5520-1307</orcidid></search><sort><creationdate>202112</creationdate><title>In vitro analysis on inhibitory effect of sodium arsenite combined with astragaloside IV on HepG2 liver cancer cells</title><author>Guo, Zhiwei ; Xia, Yajuan ; Hao, Guang ; Gao, Zhenzhen ; Li, Ran ; Yang, Ying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-604b8d537cca83d6a4c4f9b707db1d0b9c7e940abfc15f5d726e6c8d87c02c8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Astragaloside IV (AS-IV)</topic><topic>Combined treatment</topic><topic>Inhibitory effect</topic><topic>Liver cancer</topic><topic>Mechanism</topic><topic>Sodium Arsenite (NaAsO2)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guo, Zhiwei</creatorcontrib><creatorcontrib>Xia, Yajuan</creatorcontrib><creatorcontrib>Hao, Guang</creatorcontrib><creatorcontrib>Gao, Zhenzhen</creatorcontrib><creatorcontrib>Li, Ran</creatorcontrib><creatorcontrib>Yang, Ying</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Alexandria engineering journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guo, Zhiwei</au><au>Xia, Yajuan</au><au>Hao, Guang</au><au>Gao, Zhenzhen</au><au>Li, Ran</au><au>Yang, Ying</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro analysis on inhibitory effect of sodium arsenite combined with astragaloside IV on HepG2 liver cancer cells</atitle><jtitle>Alexandria engineering journal</jtitle><date>2021-12</date><risdate>2021</risdate><volume>60</volume><issue>6</issue><spage>5749</spage><epage>5764</epage><pages>5749-5764</pages><issn>1110-0168</issn><abstract>From the in vitro level, this paper explores the synergistic inhibitory effects and mechanisms of sodium arsenite (NaAsO2) and astragaloside IV(AS-IV) on HepG2 cells. By screening the optimal concentration of each drug, the authors tested the combined and separate effects of the two drugs on HepG2 cell proliferation, migration and invasion, cell cycle and apoptosis, as well as key genes and proteins of the PI3K/AKT/mTOR pathway (PI3K, p-PI3K, AKT, p-AKT, mTOR, and p-mTOR). The CCK-8 test and Transwell tests show that: the separate and joint uses of NaAsO2 and AS-IV reduced the viability and migration of cells to different degrees (p all &lt; 0.05). The scratch test results show that: although the migration rate in each treatment group declined, only NaAsO2 + AS-IV group witnessed a significant decline in migration rate (p &lt; 0.05); the percentage of S phase cells and apoptosis rate both increased significantly in each treatment group (p all &lt; 0.05). GNGT1, PI3K, p-PI3K, AKT, p-AKT, mTOR, and p-mTOR were expressed in each treatment group; Among them, GNGT1 mRNA expression increased in each treatment group, while the expressions of PI3K, p-PI3K, AKT, p-AKT, mTOR and p-mTOR gene proteins decreased in each treatment group; the indices changed most significantly in the NaAsO2 + AS-IV group (p all &lt; 0.05). By the inhibitory effect of each drug on HepG2 cells, the treatment groups could be ranked as NaAsO2 + AS-IV group &gt; NaAsO2 group &gt; AS-IV group; GNGT1 siRNA group had an opposite trend with each treatment group. From in vitro level, the above results confirm that NaAsO2 and AS-IV can inhibit HepG2, and the two drugs has a synergistic effect. In addition, the two drugs could inhibit HepG2 cells through the PI3K/AKT/mTOR signaling pathway; GNGT1 participates in the regulation of that signaling pathway.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.aej.2021.03.043</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-5520-1307</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1110-0168
ispartof Alexandria engineering journal, 2021-12, Vol.60 (6), p.5749-5764
issn 1110-0168
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_6a23d1d194514baaa3f0e0675a69af49
source Elsevier ScienceDirect Journals
subjects Astragaloside IV (AS-IV)
Combined treatment
Inhibitory effect
Liver cancer
Mechanism
Sodium Arsenite (NaAsO2)
title In vitro analysis on inhibitory effect of sodium arsenite combined with astragaloside IV on HepG2 liver cancer cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T17%3A13%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20analysis%20on%20inhibitory%20effect%20of%20sodium%20arsenite%20combined%20with%20astragaloside%20IV%20on%20HepG2%20liver%20cancer%20cells&rft.jtitle=Alexandria%20engineering%20journal&rft.au=Guo,%20Zhiwei&rft.date=2021-12&rft.volume=60&rft.issue=6&rft.spage=5749&rft.epage=5764&rft.pages=5749-5764&rft.issn=1110-0168&rft_id=info:doi/10.1016/j.aej.2021.03.043&rft_dat=%3Celsevier_doaj_%3ES1110016821002003%3C/elsevier_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c406t-604b8d537cca83d6a4c4f9b707db1d0b9c7e940abfc15f5d726e6c8d87c02c8d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true